An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501480-41-00

Acronym

TILD-21-01

Enrollment

247

Registered

2023-02-20

Start date

2023-04-06

Completion date

Unknown

Last updated

2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Brief summary

Safety - Incidence and intensity of adverse events recorded through the study period, Efficacy - Achieving ACR 20, ACR 50 and ACR 70

Interventions

DRUGIlumetri 100 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety - Incidence and intensity of adverse events recorded through the study period, Efficacy - Achieving ACR 20, ACR 50 and ACR 70	—

Countries

Czechia, Estonia, Germany, Italy, Poland, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026